PCSK9 inhibition with fully human monoclonal antibodies appears to be a very promising method to robustly decrease LDL-C levels in various patient groups, such as those with or without FH, with or without statin intolerance and at various levels of cardiovascular risk. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.